Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Humacyte Inc

HUMA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.60

▲ +9.96%

Market Cap $168.01M · Vol 1.41M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$168.01M

Micro Cap

Div Yield

N/A

EPS Growth

-30.77%

YoY

RSI (14)

42.98

Momentum

Beta

2.43

vs Market

52W High

$2.55

76.24% below

52W Low

$0.53

14.94% above

Volume

1.41M

Avg 753.61K

P/B

59.63

Price-to-book

ROE

N/A

Return on equity

Free Float

92.70%

Public shares

Shariah Compliance8 STANDARDS

✗ Humacyte Inc (HUMA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HUMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.79%

-14.48%

-39.52%

-40.12%

YTD

-37.03%

-67.83%

-86.50%

-94.00%

Financials & Valuation

TTM · Annual

Total Revenue	$2.04M
Net Income	$-40,833,000.00
Revenue Growth (YoY)	+34.88%
Gross Margin	-376.05%
Operating Margin	-5,306.04%
Net Profit Margin	-2,003.58%
ROE	N/A
ROA · ROIC	-32.12% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	74.54
P/B	59.63
P/FCF	N/A
EPS Growth	-30.77%
Outstanding Shares	277.80M

Technical Indicators

50-Day SMA	$0.80
200-Day SMA	$1.00
RSI (14)	42.98
Beta	2.43
52-Week High	$2.55
52-Week Low	$0.53

Volume Today	1.41M
Avg Daily Volume (30D)	753.61K
Relative Volume	1.87x
Volatility (10D)	120.02
Volatility (30D)	87.05
Free Float	92.70%

Analyst Consensus

BUY

Current Price $0.60

Mean Target $1.85

52W Low$0.53 52W High$2.55

Current

Target

$0.53 $2.55

Current Analyst target

+205.89% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00XPPT7T6

ISINUS44486Q1031

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.